Efficacy of metformin in the treatment of parkinsonism and depression among diabetic patients type 2
Immunopathologia Persa · 29.11.2025 · 12 (1) · e43986
DOI: 10.34172/ipp.2025.43986 ↗Kurz gefasst
Fachartikel in der Zeitschrift Immunopathologia Persa, online erschienen am 29.11.2025. Verfasst von Waleed S. El Nasser und 20 weiteren Autor:innen.
Themen: Depression
Abstract (Originalsprache)
Introduction
Parkinson’s disease (PD) often coexists with type 2 diabetes mellitus (T2DM), which may worsen disease progression. Metformin, a common diabetes medication, showed potential benefits beyond blood sugar control.
Objectives
This study examines metformin’s impact on renal function, neurological biomarkers, and clinical outcomes in patients with both PD and T2DM. Patients and Methods: This prospective case-control study involved 50 patients with both T2DM and parkinsonism, recruited from Al-Azhar university hospitals in Assiut, Egypt, between August 2024 and August 2025. Participants were divided equally into two groups; a control group receiving their standard treatment for Parkinsonism and diabetes, and a metformin-treated group receiving metformin alongside their usual therapies. Demographic data and laboratory markers were collected at baseline. Disease assessment employed standardized tools such as the unified Parkinson’s Disease Rating Scale (UPDRS) for motor function, Beck Depression Inventory (BDI) for depression severity, Hoehn and Yahr scale for disease staging, Montreal Cognitive Assessment (MoCA) for cognitive evaluation, and Parkinson’s Disease Questionnaire-39 (PDQ-39) for quality of life (QOL). All assessments were repeated after a 12-month follow-up to analyze changes relative to baseline.
Results
The findings indicated that metformin treatment offers comprehensive benefits by protecting against renal function decline, influencing neurological biomarkers, and supporting multiple clinical domains in PD. It appears to mitigate disease progression, preserve cognitive function, and enhance psychosocial well-being, while having neutral effects on vitamin status and potentially positive, though non-significant, effects on inflammatory markers. Overall, metformin not only prevents typical clinical deterioration but also actively improves motor, cognitive, psychological, and quality-of-life outcomes.
Conclusion
Metformin demonstrates promising multifaceted benefits in PD patients with T2DM by not only protecting renal function and preventing clinical deterioration but also actively improving motor, cognitive, psychological, and quality-of-life outcomes across multiple clinical domains, supporting its consideration as an adjunctive therapeutic strategy pending further research.
Zitieren
APA
Nasser, W. S. E., Fahmy, E. M., Helmy, A. M., Saleh, M. W., Hassan, A. S. S., Abdelrahman, M. A. M., Hassan, H. H., El-Hamid, B. A., Fouad, S., Etewa, M. A. M., AM, T., Mohamed, T. E., Seif, A. A., Abdella, A. M. M., Atlam, R. A. E., Hegazy, N., Abbas, M. A., Zeid, M. Y., Mohamed, K. R., …, & Badawy, H. K. (2025). Efficacy of metformin in the treatment of parkinsonism and depression among diabetic patients type 2. Immunopathologia Persa, 12(1), e43986. https://doi.org/10.34172/ipp.2025.43986
Vancouver
Nasser WSE, Fahmy EM, Helmy AM, Saleh MW, Hassan ASS, Abdelrahman MAM, et al. Efficacy of metformin in the treatment of parkinsonism and depression among diabetic patients type 2. Immunopathologia Persa. 2025;12(1):e43986. doi:10.34172/ipp.2025.43986
BibTeX
@article{Nasser2025,
author = {Nasser, Waleed S. El and Fahmy, Eman M. and Helmy, Ahmed M. and Saleh, Mohamed W. and Hassan, Amr Sherif Sherif and Abdelrahman, Mahmoud Abdallah Mansour and Hassan, Hamada H. and El-Hamid, Basem Abd and Fouad, Shimaa and Etewa, Mai Ali Mohammad and AM, Taha and Mohamed, Tayee Elsayed and Seif, Alaa Abo and Abdella, Ahmad Mohammad Mohammad and Atlam, Rashad Abd El-Nabi and Hegazy, Nelly and Abbas, Mohamed Ali and Zeid, Mohamed Y. and Mohamed, Kawashty R. and Noureldeen, Abdelrahman and Badawy, Heba Kamel},
title = {Efficacy of metformin in the treatment of parkinsonism and depression among diabetic patients type 2},
journal = {Immunopathologia Persa},
year = {2025},
volume = {12},
number = {1},
pages = {e43986},
doi = {10.34172/ipp.2025.43986}
}
EUVIMED